Gastritis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gastritis – Pipeline Review, H2 2016’, provides an overview of the Gastritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastritis

The report reviews pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastritis therapeutics and enlists all their major and minor projects

The report assesses Gastritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BCWorld Pharm Co Ltd

Boryung Pharmaceutical Co Ltd

Daewon Pharm Co Ltd

Recce Pty Ltd

RedHill Biopharma Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gastritis Overview 6

Therapeutics Development 7

Pipeline Products for Gastritis - Overview 7

Gastritis - Therapeutics under Development by Companies 8

Gastritis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Gastritis - Products under Development by Companies 12

Gastritis - Companies Involved in Therapeutics Development 13

BCWorld Pharm Co Ltd 13

Boryung Pharmaceutical Co Ltd 14

Daewon Pharm Co Ltd 15

Recce Pty Ltd 16

RedHill Biopharma Ltd 17

Gastritis - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Drug Profiles 25

BCWPA-001 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

BGC-001 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

DW-3101 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

HPi-1 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

netazepide - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ondansetron hydrochloride CR - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PMKS-005 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

RECCE-327 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Gastritis - Dormant Projects 38

Gastritis - Product Development Milestones 39

Featured News & Press Releases 39

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 39

Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 40

Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 41

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Number of Products under Development for Gastritis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Gastritis – Pipeline by BCWorld Pharm Co Ltd, H2 2016 13

Gastritis – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 14

Gastritis – Pipeline by Daewon Pharm Co Ltd, H2 2016 15

Gastritis – Pipeline by Recce Pty Ltd, H2 2016 16

Gastritis – Pipeline by RedHill Biopharma Ltd, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Gastritis – Dormant Projects, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for Gastritis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports